Clinical trial

Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.

NCT06338644

StatusUNKNOWN

Study typeOBSERVATIONAL

Start date2024-07-01

PhaseN/A

Study timeline

Study start (estimated)2024-07-01Date precision: day

Registry last updated2024-03-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Hormone-receptor-positive Breast Cancerunresolved

Human Epidermal Growth Factor 2 Negative Carcinoma of Breastunresolved

Metastatic Breast Cancerunresolved

Interventions

PalbociclibDRUG · verified · RxNorm: palbociclib

Sponsors & collaborators

Helwan Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06338644 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.